Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

TSC2 (TSC complex subunit 2)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

TSC2 overexpression	Hepatocellular Cancer	TSC2 overexpression	Hepatocellular Cancer	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
TSC2 mutation	Peripheral T-cell Lymphoma	TSC2 mutation	Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
TSC2 mutation	Endometrial Cancer	TSC2 mutation	Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC2 mutation	Renal Cell Carcinoma	TSC2 mutation	Renal Cell Carcinoma	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
TSC2 mutation	Renal Cell Carcinoma	TSC2 mutation	Renal Cell Carcinoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC2 mutation	Renal Cell Carcinoma	TSC2 mutation	Renal Cell Carcinoma	mTOR inhibitor Sensitive: C3 – Early Trials mTOR inhibitor Sensitive : C3	mTOR inhibitor Sensitive: C3 – Early Trials mTOR inhibitor Sensitive : C3
TSC2 A736V	Neurofibrosarcoma	TSC2 A736V	Neurofibrosarcoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
TSC2 A736V	Neurofibrosarcoma	TSC2 A736V	Neurofibrosarcoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC2 H1620R + TSC2 Y1650C	Renal Cell Carcinoma	TSC2 H1620R + TSC2 Y1650C	Renal Cell Carcinoma	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4
TSC2 Q1178X	Thyroid Gland Anaplastic Carcinoma	TSC2 Q1178X	Thyroid Gland Anaplastic Carcinoma	everolimus Resistant: C4 – Case Studies everolimus Resistant : C4	everolimus Resistant: C4 – Case Studies everolimus Resistant : C4
TP53 mutation + TSC2 mutation	Glioblastoma	TP53 mutation + TSC2 mutation	Glioblastoma	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4
TSC2 mutation	Pancreatic Cancer	TSC2 mutation	Pancreatic Cancer	Immunotherapy Sensitive: C4 – Case Studies Immunotherapy Sensitive : C4	Immunotherapy Sensitive: C4 – Case Studies Immunotherapy Sensitive : C4